These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20533435)

  • 1. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts.
    Van Eerdenbrugh B; Baird JA; Taylor LS
    J Pharm Sci; 2010 Sep; 99(9):3826-38. PubMed ID: 20533435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation.
    Van Eerdenbrugh B; Taylor LS
    Mol Pharm; 2010 Aug; 7(4):1328-37. PubMed ID: 20536263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A classification system to assess the crystallization tendency of organic molecules from undercooled melts.
    Baird JA; Van Eerdenbrugh B; Taylor LS
    J Pharm Sci; 2010 Sep; 99(9):3787-806. PubMed ID: 20623696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug loading into porous calcium carbonate microparticles by solvent evaporation.
    Preisig D; Haid D; Varum FJ; Bravo R; Alles R; Huwyler J; Puchkov M
    Eur J Pharm Biopharm; 2014 Aug; 87(3):548-58. PubMed ID: 24568926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisolvent membrane crystallization of pharmaceutical compounds.
    Di Profio G; Stabile C; Caridi A; Curcio E; Drioli E
    J Pharm Sci; 2009 Dec; 98(12):4902-13. PubMed ID: 19655372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of pharmaceutical solubility Via NRTL-SAC and COSMO-SAC.
    Tung HH; Tabora J; Variankaval N; Bakken D; Chen CC
    J Pharm Sci; 2008 May; 97(5):1813-20. PubMed ID: 17786984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation.
    Abramov YA; Loschen C; Klamt A
    J Pharm Sci; 2012 Oct; 101(10):3687-97. PubMed ID: 22821740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
    Kawakami K; Usui T; Hattori M
    J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments.
    Van Eerdenbrugh B; Raina S; Hsieh YL; Augustijns P; Taylor LS
    Pharm Res; 2014 Apr; 31(4):969-82. PubMed ID: 24271237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design.
    Ruether F; Sadowski G
    J Pharm Sci; 2009 Nov; 98(11):4205-15. PubMed ID: 19283772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of In Silico Solvent Screening and an Interactive Web-Based Portal for Pharmaceutical Crystallization Process Development.
    Tan JS; Hilden LR; Merritt JM
    J Pharm Sci; 2019 Aug; 108(8):2621-2634. PubMed ID: 30905703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of solution nonideality of a pseudomorphic drug system through a comprehensive thermodynamic framework for the design of a crystallization process.
    Nordstrom FL; Rasmuson A; Sheikh AY
    J Pharm Sci; 2004 Apr; 93(4):995-1004. PubMed ID: 14999735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a rational vs. high throughput approach for rapid salt screening and selection.
    Collman BM; Miller JM; Seadeek C; Stambek JA; Blackburn AC
    Drug Dev Ind Pharm; 2013 Jan; 39(1):29-38. PubMed ID: 22380522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing pharmaceutical crystallization in a flow crystallizer with ultrasound: Anti-solvent crystallization.
    Hussain MN; Jordens J; John JJ; Braeken L; Van Gerven T
    Ultrason Sonochem; 2019 Dec; 59():104743. PubMed ID: 31479884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling and prediction of cocrystal phase diagrams.
    Ainouz A; Authelin JR; Billot P; Lieberman H
    Int J Pharm; 2009 Jun; 374(1-2):82-9. PubMed ID: 19446763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of the crystallization tendency of active pharmaceutical ingredients (APIs) and nutraceuticals based on their nucleation and crystal growth behaviour in solution state.
    Rathi S; Chavan RB; Shastri NR
    Drug Deliv Transl Res; 2020 Feb; 10(1):70-82. PubMed ID: 31407270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of co-crystal phase purity by mid infrared spectroscopy and multiple curve resolution.
    Queiroz ALP; Rodrigues M; Zeglinski J; Crean AM; Sarraguça MC; Vucen S
    Int J Pharm; 2021 Feb; 595():120246. PubMed ID: 33482224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The construction, prediction and measurement of co-crystal ternary phase diagrams as a tool for solvent selection.
    Holaň J; Stěpánek F; Billot P; Ridvan L
    Eur J Pharm Sci; 2014 Oct; 63():124-31. PubMed ID: 24995701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Batch cooling crystallization and pressure filtration of sulphathiazole: the influence of solvent composition.
    Häkkinen A; Pöllänen K; Karjalainen M; Rantanen J; Louhi-Kultanen M; Nyström L
    Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):17-28. PubMed ID: 15283678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.
    Trasi NS; Baird JA; Kestur US; Taylor LS
    J Phys Chem B; 2014 Aug; 118(33):9974-82. PubMed ID: 25076138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.